genesis a digital currency group company, Overview

In 2024, the qualification examination and approval of the first batch of new materials insurance compensation was started, and the Ministry of Industry and Information Technology recently issued a notice to organize the qualification examination and approval of the first batch of new materials insurance compensation in 2024. It is clear that the enterprise applying for qualification should be an enterprise that produces and manufactures the products listed in the Catalogue for the Demonstration and Guidance of the First Application of Key New Materials (2024 Edition). It belongs to an independent legal person registered in People's Republic of China (PRC), has strong design and development, manufacturing and industrialization capabilities, has a relatively complete team of professional technicians, and has mastered the core technology and intellectual property rights of this product development. The qualification examination and approval procedures need to go through three steps: enterprise declaration, review by local industrial and information authorities or recommended units such as the central enterprise group, and expert review organized by the Ministry of Industry and Information Technology. After review, the product compensation qualification is determined, and the amount of subsidy funds is approved according to a certain proportion of the product value, and the effective period is no more than 3 years.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.The Chinese representative called for promoting the political process in Yemen and stressed respect for sovereignty and peace. On the 11th local time, the UN Security Council held a meeting on the situation in Yemen. In his speech, the Chinese representative called on all parties to the Yemen conflict to take practical actions and jointly promote the political process of resolving the Yemen issue. Geng Shuang, China's deputy permanent representative to the United Nations, said that Israel and Houthi forces have been attacking each other, and Israel recently said it would consider launching a new large-scale attack on Yemen, which is deeply worrying. At the same time, the recent dramatic changes in the situation in Syria have brought new unstable factors to the whole Middle East, and the situation in Yemen and the Red Sea may also suffer new shocks. China once again calls on Houthi armed forces to stop harassing merchant ships of various countries in the Red Sea waters and maintain the safety of the navigation channels in the Red Sea waters. At the same time, it calls on all parties concerned to maintain calm and restraint and stop actions that aggravate tensions. (CCTV News)

The yield of active 2-year treasury bonds dropped by 9BP to 1.16%, which was 9BP upside down from the current 1-year treasury bond yield. The yield of active 2-year treasury bonds dropped by 9BP to 1.16%, which was 9 BP upside down from the current 1-year treasury bond yield.Survey: More than 40% of analysts expect the Bank of Japan to raise interest rates this month, but most think that January next year is the best time. According to the latest survey, observers of the Bank of Japan predict that January is the most likely time to raise interest rates next time, but more than 40% of the respondents still expect to take action next week. According to the survey, about 52% of the 52 economists surveyed expect the Bank of Japan to raise the policy interest rate from 0.25% in January, compared with 32% in the last survey. About 44% of the respondents expect the central bank to take action at the end of the two-day meeting on December 19, down from 53% in the last survey. The survey results show that observers believe that the Bank of Japan's policy meeting this month is likely to move or not to move to a large extent. About 88% of the respondents said that the earliest possible time to raise interest rates in their risk scenarios is next week. Another equally high data shows that Japan's economic and price environment will justify raising interest rates this month.In the inter-bank market, the yield of the active 10-year treasury bond "24 Treasury Bond with Interest 11" dropped by 1bp to 1.815%. Wind data shows that compared with yield to maturity, a Chinese bond with the same term, it hit a record low.

Shennong Group has set up a new trading subsidiary in Guangxi. The enterprise search APP shows that recently, Guangxi Shennong Haiyun Trading Co., Ltd. was established, with the legal representative of He Xinyang and the registered capital of 10 million yuan. Its business scope includes: electronic product sales; Non-metallic minerals and products sales; Building materials sales, etc. Enterprise equity penetration shows that the company is wholly owned by Shennong Group.A total of 211 cases of monkeypox have been reported in France this year. The French Public Health Agency issued a communique on the 11th, saying that 211 cases of monkeypox have been reported in France this year, including 2 new cases in the past two weeks. The communique said that these monkeypox patients are all adults, including 203 males and 8 females. According to reports, after viral gene sequencing, 168 cases were infected with monkeypox virus II, of which 61 cases were further diagnosed as infected monkeypox virus IIb. (Xinhua News Agency)Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.